Skip to content
Evigrade
CriticalProkinetic, peripheral dopamine D2 receptor antagonist×Systemic antimycotics. Imidazole derivatives

Updated · Methodology

Mechanism

Ketoconazole is a strong CYP3A4 inhibitor and can raise the levels of drugs that this enzyme metabolises (ketoconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). In the liver, CYP3A4 is the main enzyme that metabolises domperidone (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With ketoconazole, the area under the concentration curve (AUC) and the peak concentration of domperidone rise about 3-fold, and a stronger interaction can be expected at higher ketoconazole doses and shorter dosing intervals (ketoconazole SmPC, EMA). Both drugs prolong the QT interval on their own. Ketoconazole inhibits the rapid component of the cardiac delayed rectifier potassium current, and 200 mg twice daily for 3–7 days increased the corrected QT interval (QTc) by a mean maximum of 6–12 ms (ketoconazole label, US Food and Drug Administration, FDA). Domperidone is associated with QT prolongation and with a higher risk of serious ventricular arrhythmias and sudden cardiac death, especially in people over 60, at doses above 30 mg a day, and with QT-prolonging drugs or CYP3A4 inhibitors (domperidone SmPC, AEMPS).

Symptoms

QT prolongation itself causes no symptoms and shows only on an electrocardiogram (ECG), while an arrhythmia causes palpitations, dizziness and fainting. With domperidone, QT prolongation and torsade de pointes have been reported very rarely (domperidone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When ketoconazole raises the levels of QT-prolonging drugs, life-threatening ventricular arrhythmias, including torsade de pointes, may occur (ketoconazole label, US Food and Drug Administration, FDA). The risk of arrhythmia is higher with low or high potassium, low magnesium or a slow heart rate (domperidone SmPC, AEMPS).

Management

The combination is contraindicated. The Spanish domperidone summary of product characteristics (SmPC) contraindicates domperidone with strong CYP3A4 inhibitors regardless of their own effect on the QT interval and names ketoconazole among the systemic azole antifungals (domperidone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The European ketoconazole SmPC is softer: it does not recommend the combination with domperidone because of the higher risk of QT prolongation (ketoconazole SmPC, European Medicines Agency, EMA). Ketoconazole is contraindicated in documented congenital or acquired prolongation of the corrected QT interval (QTc) (ketoconazole SmPC, EMA). Domperidone is contraindicated in known QTc prolongation, significant electrolyte disturbances and heart disease such as congestive heart failure (domperidone SmPC, AEMPS). Before starting ketoconazole, review all the medicines the patient already takes. Record an electrocardiogram (ECG) before treatment, within the first week and then as clinically indicated, and monitor the ECG when a QTc-prolonging drug is given at the same time (ketoconazole SmPC, EMA). If domperidone and ketoconazole have nevertheless been taken together and signs of arrhythmia appear, stop domperidone (domperidone SmPC, AEMPS). The contraindication applies to oral ketoconazole: in the European Union, ketoconazole tablets are used for endogenous Cushing's syndrome (ketoconazole SmPC, EMA). In adults, plasma ketoconazole was undetectable after the cream on the skin or the gel on the scalp, but measurable after the gel on the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Domperidone

Other interactions with Ketoconazole